



Grant Number: 5R01HL122283-02
FAIN: R01HL122283

Principal Investigator(s):
JONATHAN MARK BROWN, PHD

Project Title: Enzymatic Control of Trimethylamineoxide (TMAO)Induced Atherosclerosis

Jacqueline Whatley
Sr. Director
Cleveland Clinic Lerner College of Med. of CWRU
9500 Euclid Avenue, JN5-01
Cleveland, OH 441950001

Award e-mailed to: resadm@cwru.edu, osr@ccf.org

Period Of Performance:

Budget Period: 05/01/2015 – 04/30/2016

Project Period: 05/01/2014 – 04/30/2019

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$390,306 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to CLEVELAND CLINIC LERNER COM-CWRU in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R01HL122283. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Ann Marie Brasile Mejac
Grants Management Officer
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Additional information follows

Award Calculation (U.S. Dollars)

Federal Direct Costs	\$246,250
Federal F&A Costs	\$144,056
Approved Budget	\$390,306
Total Amount of Federal Funds Obligated (Federal Share)	\$390,306
TOTAL FEDERAL AWARD AMOUNT	\$390,306
 AMOUNT OF THIS ACTION (FEDERAL SHARE)	 \$390,306

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
2	\$390,306	\$390,306
3	\$396,250	\$396,250
4	\$396,250	\$396,250
5	\$396,250	\$396,250

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Name: Cardiovascular Diseases Research
CFDA Number: 93.837
EIN: 1341018992B9
Document Number: RHL122283A
PMS Account Type: P (Subaccount)
Fiscal Year: 2015

IC	CAN	2015	2016	2017	2018
HL	8475146	\$390,306	\$396,250	\$396,250	\$396,250

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: HHAATN / **OC:** 414E / **Released:** BRASILEA 04/14/2015
Award Processed: 01/15/2015 11:58:50 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5R01HL122283-02

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 5R01HL122283-02

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain

references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VI Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01HL122283. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Treatment of Program Income:
Additional Costs

SECTION IV – HL Special Terms and Conditions – 5R01HL122283-02

NHLBI OPERATING GUIDELINES

This award is being issued in accordance with the NHLBI FY 2015 Operating Guidelines, which can be found at: <http://www.nhlbi.nih.gov/research/funding/general/current-operating-guidelines>

NON-CATEGORICAL MODULAR GRANT AWARD

This is a Modular Grant Award without direct cost categorical breakdowns issued in accordance with the guidelines published in the NIH Grants Policy Statement. For further information regarding Modular Awards see <http://grants.nih.gov/grants/funding/modular/modular.htm> . Recipients are required to allocate and account for costs related to this award by category within their institutional accounting system in accordance with applicable cost principles.

FUTURE YEAR COMMITMENTS

Although the NHLBI remains committed at this time to funding at the recommended levels each fiscal year, fiscal constraints may necessitate future adjustments.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Ann Marie Brasile Mejac

Email: brasilea@nhlbi.nih.gov **Phone:** (301) 435-0164 **Fax:** (301) 480-0422

Program Official: Michelle Olive

Email: olivem@mail.nih.gov **Phone:** 301-443-7933

SPREADSHEET SUMMARY

GRANT NUMBER: 5R01HL122283-02

INSTITUTION: CLEVELAND CLINIC LERNER COM-CWRU

Facilities and Administrative Costs	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	58.5%	58.5%	58.5%	58.5%
F&A Cost Base 1	\$246,250	\$250,000	\$250,000	\$250,000
F&A Costs 1	\$144,056	\$146,250	\$146,250	\$146,250